Return-to-Play for Athletes With Desmosomal Arrhythmogenic Cardiomyopathy
JACC: Clinical Electrophysiology · 2026-08 · 12 (8) · 1886-1895
DOI: 10.1016/j.jacep.2026.02.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026-08. Verfasst von Roxanne Coderre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Mi…. Hauptthemen laut MEDLINE: Arrhythmogenic Right Ventricular Dysplasia, Return to Sport, Athletes, Desmosomes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Current guidelines discourage sports participation for athletes with arrhythmogenic cardiomyopathy (ACM). However, the evidence that exercise is a disease-accelerator is most compelling for PKP2-mediated ACM. OBJECTIVES: This study aims to examine management, return-to-play (RTP) decisions, outcomes, and phenotype evolution among athletes with genotype-positive ACM. METHODS: A retrospective review of electronic medical record of 1,229 patients in our Arrhythmogenic/Dilated Cardiomyopathy Registry was used to identify self-identified athletes. They were evaluated, risk stratified, and treated at Mayo Clinic Windland Smith Rice Genetic Heart Rhythm Clinic between July 2000 and February 2025. RESULTS: A total of 138 genotype-positive athletes with ACM were identified (58 women [42%], mean age of 31 ± 19 years, plakophilin [PKP2]-ACM [n = 61; 44%], desmoplakin [DSP]-ACM [n = 32; 23%]). After diagnosis of ACM, 34 athletes (25%) experienced at least 1 breakthrough cardiac event (BCE), accounting for a total of 68 events, and 6 patients experienced 14 BCEs following physician-approved RTP. During a median follow-up of 25 months (IQR: 6-71), the overall event rate for the entire cohort was 7.9 BCEs per 100 patient-years (95 % CI: 5.8-10.5), and the event rate after physician-approved RTP was 14.6 per 100 patient-years (95% CI: 7.8-24.9). During RTP period, one-half of these BCEs occurred during sports participation, whereas the remainder occurred at rest or unknown context. CONCLUSIONS: This is the first single-center cohort of patients with ACM being empowered to RTP and remain athletes. These athletes have exhibited higher rates of BCEs and disease conversion/progression than our athletes with a variety of other genetic heart diseases. Further studies are needed to determine how to further guide safe sports participation in genetically mediated ACM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA; Department of Molecular Pharmacology and Experimental Th…
Förderung
- NCATS NIH HHS
Zitieren
APA
Coderre, R., Martinez, K. A., Castrichini, M., Bos, J. M., Giudicessi, J. R., & Ackerman, M. J. (2026). Return-to-Play for Athletes With Desmosomal Arrhythmogenic Cardiomyopathy. JACC: Clinical Electrophysiology, 12(8), 1886-1895. https://doi.org/10.1016/j.jacep.2026.02.021
Vancouver
Coderre R, Martinez KA, Castrichini M, Bos JM, Giudicessi JR, Ackerman MJ. Return-to-Play for Athletes With Desmosomal Arrhythmogenic Cardiomyopathy. JACC: Clinical Electrophysiology. 2026;12(8):1886-1895. doi:10.1016/j.jacep.2026.02.021
BibTeX
@article{Coderre2026,
author = {Coderre, Roxanne and Martinez, Katherine A and Castrichini, Matteo and Bos, J Martijn and Giudicessi, John R and Ackerman, Michael J},
title = {Return-to-Play for Athletes With Desmosomal Arrhythmogenic Cardiomyopathy},
journal = {JACC: Clinical Electrophysiology},
year = {2026},
volume = {12},
number = {8},
pages = {1886--1895},
doi = {10.1016/j.jacep.2026.02.021}
}
EUVIMED